XML 42 R31.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Intangible Assets (Tables) | 3 Months Ended
--- | ---
Mar. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract] |
Schedule of Intangible Assets | Intangible assets as of March 30, 2024 and December 30, 2023 consist of the following (in $000’s):
| March 30, 2024 |  | December 30, 2023
Soin intangibles * | $ | 19,293 |  |  | $ | 19,293 |
Patents and domains | 4 |  |  | 4 |
Intangible assets | 19,297 |  |  | 19,297 |
Less accumulated amortization | (2,090) |  |  | (1,451) |
Total intangible assets | $ | 17,207 |  |  | $ | 17,846 |
*The Soin intangibles acquired by the Company consist of the following: 1.Two pending patents and one approved patent related to the methods of using low-dose Naltrexone to treat chronic pain; 2.Final formula for Naltrexone; and 3.Orphan drug designation as approved by the FDA.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2 + Details
Name: | us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration